{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:18:33Z","timestamp":1793837913643,"version":"4.6.1"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.msard.2026.107140","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:52:17Z","timestamp":1773474737000},"page":"107140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Failed, Inconclusive or Interrupted Trials in Multiple Sclerosis: 2020-2024 Update"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-3548","authenticated-orcid":false,"given":"Vito AG","family":"Ricigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Szejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gomez-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof W","family":"Selmaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107140_bib0105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s00415-023-12113-2","article-title":"The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial","volume":"271","author":"Abdelgaied","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0097","doi-asserted-by":"crossref","first-page":"892","DOI":"10.21037\/atm.2020.03.131","article-title":"Opicinumab: is it a potential treatment for multiple sclerosis?","volume":"8","author":"Ahmed","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.msard.2026.107140_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106185","article-title":"RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis","volume":"93","author":"Aktas","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0134","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10787-023-01240-x","article-title":"The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects","volume":"31","author":"Al-Kuraishy","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.msard.2026.107140_bib0133","doi-asserted-by":"crossref","first-page":"e1729","DOI":"10.1212\/WNL.0000000000207777","article-title":"Exploring the role of plasma lipids and statin interventions on multiple sclerosis risk and severity: a Mendelian randomization study","volume":"101","author":"Almramhi","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1177392818785136","article-title":"DRESS syndrome and daclizumab failure\u2014were potentially dangerous signs missed in clinical trials?","volume":"12","author":"Avasarala","year":"2018","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.msard.2026.107140_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115820","article-title":"Tea-break with epigallocatechin gallate derivatives: powerful polyphenols of great potential for medicine","volume":"261","author":"Bakun","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.msard.2026.107140_bib0042","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0056","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0085","doi-asserted-by":"crossref","first-page":"e981","DOI":"10.1212\/NXI.0000000000000981","article-title":"Epigallocatechin gallate in relapsing-remitting multiple sclerosis: a randomized, placebo-controlled trial","volume":"8","author":"Bellmann-Strobl","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2026.107140_bib0121","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00415-020-10210-0","article-title":"Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension","volume":"268","author":"Bergman","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.msard.2019.02.013","article-title":"Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement","volume":"30","author":"Bhargava","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0136","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086414","article-title":"Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK","volume":"14","author":"Blackstone","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.msard.2026.107140_bib0029","article-title":"No early effect of intrathecal rituximab in progressive multiple sclerosis (EFFRITE clinical trial)","volume":"2021","author":"Bonnan","year":"2021","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.msard.2026.107140_bib0061","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jns.2011.02.019","article-title":"Insight into the mechanism of laquinimod action","volume":"306","author":"Br\u00fcck","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2026.107140_bib0126","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s13311-020-00880-z","article-title":"Relapses during high-dose biotin treatment in progressive multiple sclerosis: a case-crossover and propensity score-adjusted prospective cohort","volume":"17","author":"Branger","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2026.107140_bib0090","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.msard.2026.107140_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168834","article-title":"Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis","volume":"12","author":"Brochet","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2026.107140_bib0076","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1474-4422(21)00179-4","article-title":"Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study","volume":"20","author":"Brown","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0067","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/acn3.51662","article-title":"Remyelination varies between and within lesions in multiple sclerosis following bexarotene","volume":"9","author":"Brown","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0037","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0038","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo\u2011controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104068","article-title":"Update on treatment in multiple sclerosis","volume":"50","author":"Callegari","year":"2021","journal-title":"Presse Med"},{"key":"10.1016\/j.msard.2026.107140_bib0075","first-page":"1016","article-title":"Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis","volume":"8","author":"Chandraratna","year":"2016","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.msard.2026.107140_bib0135","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107140_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01039-6","article-title":"Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial","author":"Chataway","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107140_bib0031","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ane.13344","article-title":"Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial","volume":"143","author":"Cheshmavar","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.msard.2026.107140_bib0054","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1073\/pnas.1002716107","article-title":"Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast","volume":"107","author":"Cho","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.msard.2026.107140_bib0093","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bbrc.2011.12.029","article-title":"Erythropoietin promotes oligodendrogenesis and myelin repair following lysolecithin-induced injury in spinal cord slice culture","volume":"417","author":"Cho","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.msard.2026.107140_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.015","article-title":"The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"318","author":"Chu","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2026.107140_bib0062","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(08)60918-6","article-title":"Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"371","author":"Comi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107140_bib0063","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","article-title":"Placebo-controlled trial of oral laquinimod for multiple sclerosis","volume":"366","author":"Comi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0002","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0066","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/13524585211032803","article-title":"CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis","volume":"28","author":"Comi","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group","volume":"339","author":"Confavreux","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0124","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1177\/1352458519894713","article-title":"High-dose biotin in progressive multiple sclerosis: a prospective study of 178 patients in routine clinical practice","volume":"26","author":"Couloume","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0127","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1474-4422(20)30347-1","article-title":"Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Cree","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","article-title":"Reduced inflammation in relapsing\u2013remitting multiple sclerosis after therapy switch to rituximab","volume":"87","author":"de Flon","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362629","article-title":"A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial","volume":"15","author":"De Keersmaecker","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.msard.2026.107140_bib0072","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1083\/jcb.201505119","article-title":"Vitamin D receptor\u2013retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation","volume":"211","author":"de la Fuente","year":"2015","journal-title":"J Cell Biol"},{"key":"10.1016\/j.msard.2026.107140_bib0101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nchembio.83","article-title":"Identification of RIP1 kinase as a specific cellular target of necrostatins","volume":"4","author":"Degterev","year":"2008","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.msard.2026.107140_bib0007","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1177\/1352458518792403","article-title":"A case of immune-mediated encephalitis related to daclizumab therapy","volume":"25","author":"Devlin","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0091","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/brain\/awh365","article-title":"Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis","volume":"128","author":"Diem","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107140_bib0103","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1750-3639.2010.00401.x","article-title":"Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis","volume":"20","author":"Dziedzic","year":"2010","journal-title":"Brain Pathol"},{"key":"10.1016\/j.msard.2026.107140_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103159","article-title":"High-dose biotin for multiple sclerosis: a systematic review and meta-analyses of randomized controlled trials","volume":"55","author":"Espiritu","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0057","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 trial of ibudilast in progressive multiple sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0052","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0165-5728(98)00251-3","article-title":"Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats","volume":"95","author":"Fujimoto","year":"1999","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2026.107140_bib0116","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/ph14060495","article-title":"Human endogenous retrovirus as therapeutic targets in neurologic disease","volume":"14","author":"Gim\u00e9nez-Orenga","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.msard.2026.107140_bib0024","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.msard.2016.05.010","article-title":"Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0065","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000010284","article-title":"A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis","volume":"95","author":"Giovannoni","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0021","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107140_bib0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.msard.2018.06.002","article-title":"A phase II baseline-versus-treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing-remitting multiple sclerosis as determined by gadolinium-enhanced MRI: the INSPIRE study","volume":"24","author":"Gold","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0022","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-020-09835-y","article-title":"Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study","volume":"267","author":"Gold","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0132","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","article-title":"Statin therapy and autoimmune disease: from protein prenylation to immunomodulation","volume":"6","author":"Greenwood","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.msard.2026.107140_bib0047","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.94.15_supplement.808","article-title":"Central effects of BTK inhibition in neuroinflammation","volume":"94","author":"Gruber","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101812","article-title":"Idebenone: when an antioxidant is not an antioxidant","volume":"38","author":"Gueven","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.msard.2026.107140_bib0017","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/13524585211024997","article-title":"Efficacy and safety of temelimab in multiple sclerosis: results of a randomized phase 2b and extension study","volume":"28","author":"Hartung","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0118","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0004","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0036","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdov\u00e1","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0028","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0043","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41582-022-00624-x","article-title":"The role of glial cells in multiple sclerosis disease progression","volume":"18","author":"Healy","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0123","first-page":"381","article-title":"Intersections of pathways involving biotin and iron relative to therapeutic mechanisms for progressive multiple sclerosis","volume":"22","author":"Heidker","year":"2016","journal-title":"Discov Med"},{"key":"10.1016\/j.msard.2026.107140_bib0030","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1212\/WNL.0000000000006916","article-title":"Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis","volume":"92","author":"Honce","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0071","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nn.2702","article-title":"Retinoid X receptor gamma signaling accelerates CNS remyelination","volume":"14","author":"Huang","year":"2011","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.msard.2026.107140_bib0034","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0012","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0020","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0003","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420987941","article-title":"Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination","volume":"14","author":"Kappos","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0016","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/1352458516662727","article-title":"ACCLAIM: a randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis","volume":"23","author":"Khoury","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0087","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1096\/fj.04-2493fje","article-title":"Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1\/-2","volume":"19","author":"Kilic","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.msard.2026.107140_bib0079","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.3390\/ijms23074004","article-title":"Epigallocatechin gallate protects against hypoxia-induced inflammation in microglia via NF-\u03baB suppression and Nrf-2\/HO-1 activation","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.msard.2026.107140_bib0089","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.expneurol.2007.01.017","article-title":"Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection","volume":"205","author":"King","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0026","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102434","article-title":"Idebenone does not inhibit disability progression in primary progressive MS","volume":"45","author":"Kosa","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0040","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13311-022-01246-3","article-title":"What have failed, interrupted, and withdrawn antibody therapies in multiple sclerosis taught us?","volume":"19","author":"Kr\u00e4mer","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2026.107140_bib0044","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0086","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.mcn.2005.04.009","article-title":"Erythropoietin promotes regeneration of adult CNS neurons via Jak2\/Stat3 and PI3K\/AKT pathway activation","volume":"29","author":"Kretz","year":"2005","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.msard.2026.107140_bib0096","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1474-4422(21)00322-7","article-title":"Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study","volume":"20","author":"Lagr\u00e8ze","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0033","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2026.107140_bib0025","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","article-title":"GFAP\u03b1 IgG-associated encephalitis upon daclizumab treatment of MS","volume":"5","author":"Luessi","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2026.107140_bib0088","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2004.09.006","article-title":"Erythropoietin in the brain: can the promise to protect be fulfilled?","volume":"25","author":"Maiese","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.msard.2026.107140_bib0046","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BPL-200100","article-title":"Bruton's tyrosine kinase inhibition promotes myelin repair","volume":"5","author":"Martin","year":"2020","journal-title":"Brain Plast"},{"key":"10.1016\/j.msard.2026.107140_bib0125","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s13311-020-00926-2","article-title":"Relapses in patients treated with high-dose biotin for progressive multiple sclerosis","volume":"18","author":"Mathais","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2026.107140_bib0068","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/acn3.51595","article-title":"Remyelination in humans due to a retinoid-X receptor agonist is age-dependent","volume":"9","author":"McMurran","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0069","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1177\/13524585241233177","article-title":"Bexarotene leads to durable improvements in visual evoked potential latency: a follow-up study of the Cambridge Centre for Myelin Repair One trial","volume":"30","author":"McMurran","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0048","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0049","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0102","unstructured":"Montalban X. A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05630547."},{"key":"10.1016\/j.msard.2026.107140_bib0094","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12974-017-0976-5","article-title":"Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms","volume":"14","author":"Moransard","year":"2017","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.msard.2026.107140_bib0119","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","article-title":"Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial","volume":"74","author":"Naismith","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0058","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1212\/WNL.0000000000011314","article-title":"Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study","volume":"96","author":"Naismith","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0059","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/13524585231224702","article-title":"Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis","volume":"30","author":"Nakamura","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0070","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1093\/brain\/awv289","article-title":"Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination","volume":"138","author":"Natrajan","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107140_bib0104","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","article-title":"Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis","volume":"73","author":"Negrotto","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0006","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41582-022-00675-0","article-title":"Emerging therapies to target CNS pathophysiology in multiple sclerosis","volume":"18","author":"Oh","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0051","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0082","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.phrs.2015.12.027","article-title":"Epigallocatechin gallate and mitochondria: a story of life and death","volume":"104","author":"Oliveira","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.msard.2026.107140_bib0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fchem.2014.00050","article-title":"Human isoprenoid synthase enzymes as therapeutic targets","volume":"2","author":"Park","year":"2014","journal-title":"Front Chem"},{"key":"10.1016\/j.msard.2026.107140_bib0115","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/1352458512441381","article-title":"Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease","volume":"18","author":"Perron","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0039","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14737175.2016.1176531","article-title":"Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010\u20132015","volume":"16","author":"Pfeuffer","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.msard.2026.107140_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103539","article-title":"Remyelination trial failures: repercussions of ignoring neurorehabilitation and exercise in repair","volume":"58","author":"Ploughman","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2026.107140_bib0010","first-page":"e359","article-title":"Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy","volume":"5","author":"Rauer","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2026.107140_bib0050","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0141","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/biomedicines13020357","article-title":"Identifying biomarkers for remyelination and recovery in multiple sclerosis : a measure of progress","volume":"13","author":"Ricigliano","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.msard.2026.107140_bib0032","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40259-020-00435-w","article-title":"Failed, interrupted, or inconclusive trials on immunomodulatory treatment strategies in multiple sclerosis: update 2015\u20132020","volume":"34","author":"Rolfes","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.msard.2026.107140_bib0074","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1191\/1352458502ms858oa","article-title":"Retinol measurements and retinoid receptor gene expression in patients with multiple sclerosis","volume":"8","author":"Royal","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0084","doi-asserted-by":"crossref","first-page":"e987","DOI":"10.1212\/NXI.0000000000000964","article-title":"Epigallocatechin gallate in progressive MS: a randomized, placebo-controlled trial","volume":"8","author":"Rust","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2026.107140_bib0114","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2174\/157015911795596568","article-title":"Human endogenous retroviruses in multiple sclerosis: potential for novel neuro-pharmacological research","volume":"9","author":"Ryan","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.msard.2026.107140_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","article-title":"A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis","volume":"72","author":"S\u00fchs","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0083","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.3390\/nu16162723","article-title":"The effects of epigallocatechin-3-gallate nutritional supplementation in the management of multiple sclerosis: a systematic review of clinical trials","volume":"16","author":"Schuldesz","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.msard.2026.107140_bib0077","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/1440-1681.13691","article-title":"Epigallocatechin gallate for Parkinson\u2019s disease","volume":"49","author":"Sergi","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.msard.2026.107140_bib0013","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jns.2015.02.019","article-title":"ATON: results from a phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis","volume":"351","author":"Sergott","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2026.107140_bib0073","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s12035-021-02709-y","article-title":"Retinoid X receptor: cellular and biochemical roles of nuclear receptor with a focus on neuropathological involvement","volume":"59","author":"Sharma","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.msard.2026.107140_bib0109","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ana.10301","article-title":"Treatment of multiple sclerosis with the pregnancy hormone estriol","volume":"52","author":"Sicotte","year":"2002","journal-title":"Ann Neurol"},{"issue":"Suppl","key":"10.1016\/j.msard.2026.107140_bib0014","article-title":"Efficacy and safety of tabalumab in patients with relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled study (P3.397)","volume":"90","author":"Silk","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0092","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","article-title":"Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system","volume":"6","author":"Sir\u00e9n","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2026.107140_bib0110","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.4049\/jimmunol.171.11.6267","article-title":"Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol","volume":"171","author":"Soldan","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.msard.2026.107140_bib0005","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2026.107140_bib0140","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jamaneurol.2013.3553","article-title":"The road not taken: antigen-specific therapy and neuroinflammatory disease","volume":"70","author":"Steinman","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0009","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1177\/1352458518819098","article-title":"Severe meningo-\/encephalitis after daclizumab therapy for multiple sclerosis","volume":"25","author":"Stork","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0111","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jri.2009.06.262","article-title":"Progesterone in pregnancy; receptor-ligand interaction and signaling pathways","volume":"83","author":"Szekeres-Bartho","year":"2009","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.msard.2026.107140_bib0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/135245850000600208","article-title":"Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials","volume":"6","author":"Tan","year":"2000","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0098","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/NXI.0000000000000018","article-title":"Randomized phase I trials of the safety\/tolerability of anti-LINGO-1 monoclonal antibody BIIB033","volume":"1","author":"Tran","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2026.107140_bib0131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","article-title":"Statins: mechanisms of neuroprotection","volume":"88","author":"van der Most","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.msard.2026.107140_bib0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1212\/01.wnl.0000325915.00112.61","article-title":"CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial","volume":"71","author":"Viglietta","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107140_bib0064","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","article-title":"A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis","volume":"261","author":"Vollmer","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0108","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrneurol.2015.53","article-title":"Multiple sclerosis and pregnancy in the 'treatment era","volume":"11","author":"Vukusic","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0112","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jns.2009.08.056","article-title":"The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART\u2019MUS) trial: rationale, objectives and state of advancement","volume":"286","author":"Vukusic","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2026.107140_bib0113","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1177\/1352458520978218","article-title":"Oral nomegestrol acetate and transdermal 17-\u03b2-estradiol for preventing post-partum relapses in multiple sclerosis: the POPARTMUS study","volume":"27","author":"Vukusic","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0081","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/nu16040559","article-title":"Epigallocatechin gallate for the treatment of benign and malignant gynecological diseases: focus on epigenetic mechanisms","volume":"16","author":"W\u0142odarczyk","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.msard.2026.107140_bib0139","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2013.3022","article-title":"Transdermal application of myelin peptides in multiple sclerosis treatment","volume":"70","author":"Walczak","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0008","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/1352458518791374","article-title":"Immune-mediated encephalitis with daclizumab: The final nail","volume":"25","author":"Williams","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2026.107140_bib0019","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0045","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1074\/jbc.M308722200","article-title":"Bruton's tyrosine kinase phosphorylates cAMP-responsive element-binding protein at serine 133 during neuronal differentiation in immortalized hippocampal progenitor cells","volume":"279","author":"Yang","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.msard.2026.107140_bib0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","article-title":"Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases","volume":"20","author":"Yuan","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.msard.2026.107140_bib0138","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1407257","article-title":"The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care - updates at the 2023 plenary event","volume":"15","author":"Zaratin","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2026.107140_bib0080","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.3390\/ijms22084027","article-title":"Epigallocatechin gallate for management of heavy metal-induced oxidative stress: mechanisms of action, efficacy, and concerns","volume":"22","author":"Zwolak","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:23:56Z","timestamp":1780327436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":141,"alternative-id":["S2211034826001768"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107140","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Failed, Inconclusive or Interrupted Trials in Multiple Sclerosis: 2020-2024 Update","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107140"}}